From a methodological standpoint, BPC-157 experiments often involve titration across multiple concentrations, time-course sampling, and pairing with imaging or molecular assays
We evaluate at the end of each cycle before deciding whether to repeat, adjust the dose, add a stack partner like TB-500, or transition to a maintenance approach
BPC = body protection compound, ECM = extracellular matrix, TB = thymosin beta, GHK-Cu = glycine-histidyl-lysine-copper, NO = nitric oxide, PI3K = phosphoinositide 3-kinase, AKT = protein kinase B, VEGF = vascular endothelial growth factor, eNOS = endothelial nitric oxide synthase, TGF-B = transforming growth factor-beta, FAK = focal adhesion kinase, MAPK = mitogen-activated protein kinase, NF-kB = nuclear factor kappa light chain enhancer of activated B cells, MMP = matrix metalloproteinases, NRF2 = nuclear factor erythroid 2-related factor 2
Balanced approach: BPC-157 + Ipamorelin combines one healing peptide with one GH secretagogue, addressing both concerns without complexity